Abstract
Objective: Kawasaki disease (KD) poses a significant risk of childhood-acquired coronary artery disease. There is a notable scarcity of comprehensive KD data from low- and middleincome Arab countries, giving rise to concerns about the underestimation of KD outcomes. To bridge these gaps, the Kawasaki disease Arab initiative (Kawarabi) was established to reinforce education, advocacy, and enhance patients' health outcomes. This project's primary objective is to assess the economic burden and disease-related costs affecting KD management in the Arab world, contextualized within the economic status and healthcare infrastructure of each respective country. Materials and Methods: The project employs a thorough pharmacoeconomic (PE) analysis, emphasizing societal implications, including patient expenses, hospital costs, and impacts on both the public healthcare system and private insurers. A multifaceted cost analysis methodology considers the impact of delays in acute management and potential cardiac complications, addressing hypothetical scenarios to quantify costs associated with different outcomes. Results: Unique perspectives of PEs in Arab countries and its crucial role in informing healthcare decision-making are analyzed. The project delves into the transformative role of PEs in healthcare systems. The project's exploration of KD in the Arab world anticipates significant contributions to the global understanding of KD challenges. The commitment to overcoming obstacles and addressing health disparities through the transformative lens of PEs reflects a dedication to making a positive impact on KD-related public health. Conclusion: The project is emphasized by offering actionable recommendations for KD management in low- to moderate-income Arab countries, in particular, and the Middle East, in general.